Glycated human serum albumin induces NF-κB activation and endothelial nitric oxide synthase uncoupling in human umbilical vein endothelial cells

J Diabetes Complications. 2015 Nov-Dec;29(8):984-92. doi: 10.1016/j.jdiacomp.2015.07.016. Epub 2015 Jul 18.

Abstract

Aims: Non-enzymatic glycated proteins could mediate diabetes vascular complications, but the molecular mechanisms are unknown. Our objective was to find new targets involved in the glycated human serum albumin (gHSA)-enhanced extracellular reactive oxygen species (ROS) production in human endothelial cells.

Methods & results: Some nuclear factors and phosphorylation cascades were analysed. gHSA activated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which up-regulated NOX4 and P22PHOX and enhanced ROS production. Pharmacological inhibition of NF-κB reversed gHSA-enhanced NOX4 expression and decreased gHSA-induced ROS production in extra- and intracellular spaces. The inhibition of activator protein-1 (AP-1) induced a rise in NOX4 and P22PHOX subunit expression and a down-regulation of endothelial nitric oxide synthase (eNOS). AP-1 inhibition also enhanced extracellular ROS production in the presence of serum albumin, but not with gHSA. These results were explained by the eNOS uncoupling induced by gHSA, also demonstrated in this study. Phosphatidylinositol 3-kinase or mitogen-activated protein kinase kinase 1/2 did not show to be involved in gHSA-induced ROS production.

Conclusions: All together, the results suggested that gHSA-enhanced ROS production in endothelium is mediated by: 1) NF-κB activation and subsequence up-regulation of NADPH oxidase, 2) eNOS uncoupling. AP-1, although is not directly affected by gHSA, is another target for regulating NADPH oxidase and eNOS expression in endothelial cells.

Keywords: Amadori adducts; Endothelial dysfunction; Glycated albumin; NF-κB; Reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Survival / drug effects
  • Cells, Cultured
  • Diabetic Angiopathies / metabolism*
  • Diabetic Angiopathies / pathology
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism*
  • Endothelium, Vascular / pathology
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Glycated Serum Albumin
  • Glycation End Products, Advanced
  • Human Umbilical Vein Endothelial Cells / cytology
  • Humans
  • NADPH Oxidase 4
  • NADPH Oxidases / chemistry
  • NADPH Oxidases / genetics
  • NADPH Oxidases / metabolism
  • NF-kappa B p50 Subunit / agonists*
  • NF-kappa B p50 Subunit / antagonists & inhibitors
  • NF-kappa B p50 Subunit / metabolism
  • Nitric Oxide / agonists
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / antagonists & inhibitors*
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress* / drug effects
  • Protein Synthesis Inhibitors / pharmacology
  • Reactive Oxygen Species / agonists
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Serum Albumin / antagonists & inhibitors
  • Serum Albumin / metabolism*
  • Serum Albumin, Human
  • Superoxides / agonists
  • Superoxides / antagonists & inhibitors
  • Superoxides / metabolism
  • Transcription Factor AP-1 / antagonists & inhibitors
  • Transcription Factor AP-1 / metabolism

Substances

  • ALB protein, human
  • Enzyme Inhibitors
  • Glycation End Products, Advanced
  • NF-kappa B p50 Subunit
  • NFKB1 protein, human
  • Protein Synthesis Inhibitors
  • Reactive Oxygen Species
  • Serum Albumin
  • Transcription Factor AP-1
  • Superoxides
  • Nitric Oxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • NADPH Oxidase 4
  • NADPH Oxidases
  • NOX4 protein, human
  • CYBA protein, human
  • Serum Albumin, Human
  • Glycated Serum Albumin